Researchers Submit Patent Application, "Methods And Materials For Treating Proteinopathies", for Approval (USPTO 20240226230).

A patent application has been submitted for methods and materials to treat proteinopathies, including Alzheimer's disease and frontotemporal dementia. The application suggests using importin polypeptides and fragments to reduce neurodegeneration and aggregation of TAR DNA-binding protein 43 (TDP-43) polypeptides in the central nervous system. These methods involve administering the importin polypeptides or nucleic acids encoding them to mammals, potentially reducing symptoms associated with TDP-43 proteinopathies. This patent application offers a unique opportunity for the treatment of proteinopathies and provides potential therapeutic options for individuals at risk of developing these conditions. [Extracted from the article]

Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)